Elara Capital observes that Aurobindo Pharma has 14 biosimilars in the pipeline. The company has also filed 3 biosimilars for ...

Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in ...

Motilal Oswal is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in its ...

Recent hiccups related to manufacturing plant issues and tariff uncertainties have led to volatility in earnings and, ...

Aurobindo Pharma's net profit fell 10.2 per cent Y-o-Y to ₹824 crore in Q1FY26, as against ₹918 crore in the same quarter ...

Aurobindo Pharma Ltd. reported a 10.3 per cent year-on-year (YoY) decline in consolidated net profit to Rs 824.2 crore in Q1 ...

Indian drugmaker Aurobindo Pharma reported a lower first-quarter profit on Monday, as expenses grew faster than revenue - stung by weak prices in the key U.S. market.

Aurobindo Pharma reported a 10.2% YoY decline in Q1 net profit to ₹824.2 crore, missing CNBC-TV18 estimates. Revenue rose 4%, ...

Brokerage have shared views on multiple stocks today (August 6) post quarterly results. The top stocks that are on the radar ...

Aurobindo Pharma's Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA), margins and net profit was also ...

Aurobindo Pharma on Monday reported a 10 per cent decline in its consolidated net profit to Rs 824 crore for the June quarter ...

Aurobindo Pharma's consolidated net profit fell by 10.2% to ₹824 crore in Q1, despite a 4% increase in revenue driven by European and growth market sales.